Product Description
Lemborexant is a medication used in the management and treatment of insomnia. It is in the dual orexin antagonist class of medications. This activity outlines the indications, actions, and contraindications for lemborexant as a valuable agent in managing insomnia. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK559070/)
Mechanisms of Action: OX1R Antagonist,OX2R Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Canada | Hong Kong | India | Indonesia | Israel | Japan | Malaysia | Mexico | Philippines | Singapore | Taiwan | United Arab Emirates | United States
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, Korea, Taiwan, United States, Unknown Location
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Insomnia
Phase 2: Delirium
Phase 1: Chronic Obstructive Pulmonary Disease|Sleep Apnea, Obstructive
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PROTEX | P2 |
Not yet recruiting |
Delirium |
2027-01-30 |
|
| E2006-J082-204 | P2 |
Completed |
Insomnia |
2024-04-26 |
|
| E2006-J086-311 | P3 |
Completed |
Insomnia |
2023-03-17 |
90% |
| E2006-A001-113 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease|Sleep Apnea, Obstructive |
2022-02-10 |